Literature DB >> 25614282

Role of oral anticoagulants in patients after an acute coronary syndrome.

Edward T Carreras1, Jessica L Mega2.   

Abstract

After an acute coronary syndrome, patients continue to be at risk of adverse cardiovascular events despite treatment with the current standard of antithrombotic therapy. The risk may be in part secondary to thrombin, which remains elevated after an acute coronary syndrome event. Several studies have investigated the utility of adding oral anticoagulation to post-acute coronary syndrome medical regimens, with the most promising results coming from the addition of low-dose oral direct anticoagulants. Focusing on optimal dosing strategies and applying therapies to the appropriate populations provide the ability to maximize benefit and minimize risk.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  acute coronary syndrome; anticoagulation; non-vitamin K dependent oral anticoagulants

Mesh:

Substances:

Year:  2015        PMID: 25614282     DOI: 10.1161/ATVBAHA.114.303401

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  5 in total

Review 1.  Novel oral anticoagulants for acute coronary syndrome.

Authors:  April Robinson; Delilah McCarty; Janine Douglas
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-10-07

2.  Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation.

Authors:  Lluis Pujadas-Mestres; Irene Lopez-Vilchez; Eduardo Arellano-Rodrigo; Joan Carles Reverter; Antonio Lopez-Farre; Maribel Diaz-Ricart; Juan Jose Badimon; Gines Escolar
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

3.  Dysregulation of serum miR-361-5p serves as a biomarker to predict disease onset and short-term prognosis in acute coronary syndrome patients.

Authors:  Wenqing Zhang; Guannan Chang; Liya Cao; Gang Ding
Journal:  BMC Cardiovasc Disord       Date:  2021-02-05       Impact factor: 2.298

4.  microRNA-3646 serves as a diagnostic marker and mediates the inflammatory response induced by acute coronary syndrome.

Authors:  Jinming Yu; Yongmei Li; Deguo Leng; Cheng Cao; Yongzhi Yu; Yijuan Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Considerations for use of direct oral anticoagulants in arterial disease.

Authors:  Deborah M Siegal; Sonia S Anand
Journal:  Res Pract Thromb Haemost       Date:  2021-05-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.